Sandbox g32: Difference between revisions

Jump to navigation Jump to search
← Older edit
VisualWikitext
Gerald Chi- (talk | contribs)
Bureaucrats, bureaucrats, nocaptcha, oversight, smwadministrator, Administrators, Widget editors
7,699 edits
Gerald Chi- (talk | contribs)
Bureaucrats, bureaucrats, nocaptcha, oversight, smwadministrator, Administrators, Widget editors
7,699 edits
mNo edit summary
 
(2 intermediate revisions by the same user not shown)
Line 1: Line 1:
===Meningitis, bacteria===
* Bacterial meningitis<ref>{{Cite journal| doi = 10.1086/425368| issn = 1537-6591| volume = 39| issue = 9| pages = 1267–1284| last1 = Tunkel| first1 = Allan R.| last2 = Hartman| first2 = Barry J.| last3 = Kaplan| first3 = Sheldon L.| last4 = Kaufman| first4 = Bruce A.| last5 = Roos| first5 = Karen L.| last6 = Scheld| first6 = W. Michael| last7 = Whitley| first7 = Richard J.| title = Practice guidelines for the management of bacterial meningitis| journal = Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America| date = 2004-11-01| pmid = 15494903}}</ref>
* Bacterial meningitis<ref>{{Cite journal| doi = 10.1086/425368| issn = 1537-6591| volume = 39| issue = 9| pages = 1267–1284| last1 = Tunkel| first1 = Allan R.| last2 = Hartman| first2 = Barry J.| last3 = Kaplan| first3 = Sheldon L.| last4 = Kaufman| first4 = Bruce A.| last5 = Roos| first5 = Karen L.| last6 = Scheld| first6 = W. Michael| last7 = Whitley| first7 = Richard J.| title = Practice guidelines for the management of bacterial meningitis| journal = Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America| date = 2004-11-01| pmid = 15494903}}</ref>


Line 89: Line 87:
:::::* Preferred regimen: [[Ceftriaxone]] 4 g IV q12–24h {{or}} [[Cefotaxime]] 8–12 g/day q4–6h
:::::* Preferred regimen: [[Ceftriaxone]] 4 g IV q12–24h {{or}} [[Cefotaxime]] 8–12 g/day q4–6h
:::::* Alternative regimen: [[Chloramphenicol]] 4–6 g/day IV q6h {{or}} [[Gatifloxacin]] 400 mg/day IV q24h {{or}} [[Moxifloxacin]] 400 mg/day IV q24h {{or}} [[Meropenem]] 6 g/day IV q8h
:::::* Alternative regimen: [[Chloramphenicol]] 4–6 g/day IV q6h {{or}} [[Gatifloxacin]] 400 mg/day IV q24h {{or}} [[Moxifloxacin]] 400 mg/day IV q24h {{or}} [[Meropenem]] 6 g/day IV q8h
xx


::* '''Listeria monocytogenes'''
::* '''Listeria monocytogenes'''
Line 110: Line 106:
::* '''Haemophilus influenzae'''
::* '''Haemophilus influenzae'''
:::* β-Lactamase negative
:::* β-Lactamase negative
::::* Preferred regimen: [[ampicillin]] 12g 6 times per day
::::* Preferred regimen: [[Ampicillin]] 12 g/day IV q4h
::::* Alternative regimen: [[Ceftriaxone]] 4g bid/OD {{or}} [[cefotaxime]] 8-12g 4-6 times per day {{or}} [[Cefepime]] 6g tid {{or}} [[chloramphenicol]] 4-6g qid {{or}} [[Gatifloxacin]] 400 mg OD {{or}} [[moxifloxacin]] 400 mg OD
::::* Alternative regimen: [[Ceftriaxone]] 4 g IV q12–24h {{or}} [[Cefotaxime]] 8–12 g/day q4–6h {{or}} [[Cefepime]] 6 g/day IV q8h {{or}} [[Chloramphenicol]] 4–6 g/day IV q6h {{or}} [[Gatifloxacin]] 400 mg/day IV q24h {{or}} [[Moxifloxacin]] 400 mg/day IV q24h
:::* β-Lactamase positive
:::* β-Lactamase positive
::::* Preferred regimen: [[Ceftriaxone]] 4g bid/OD {{or}} [[cefotaxime]] 8-12g 4-6 times per day  
::::* Preferred regimen: [[Ceftriaxone]] 4 g IV q12–24h {{or}} [[Cefotaxime]] 8–12 g/day q4–6h
::::* Alternative regimen: [[Cefepime]] 6g tid {{or}} [[chloramphenicol]] 4-6g qid {{or}} [[Gatifloxacin]] 400 mg OD {{or}} [[moxifloxacin]] 400 mg OD
::::* Alternative regimen: [[Cefepime]] 6 g/day IV q8h {{or}} [[Chloramphenicol]] 4–6 g/day IV q6h {{or}} [[Gatifloxacin]] 400 mg/day IV q24h {{or}} [[Moxifloxacin]] 400 mg/day IV q24h


::* '''Staphylococcus aureus'''
:::* Methicillin susceptible
::::* Preferred regimen: [[Nafcillin]] 9–12 g/day IV q4h {{or}} [[Oxacillin]] 9–12 g/day IV q4h
::::* Alternative regimen: [[Vancomycin]] 30–45 mg/kg/day IV q8–12h {{or}} [[Meropenem]] 6 g/day IV q8h


::* Staphylococcus aureus
:::* Methicillin susceptible
::::* Preferred regimen:  [[Nafcillin]] 9–12 g 6 times per day {{or}} [[oxacillin]] 9–12 g 6 times per day
::::* Alternative regimen: [[Vancomycin]] 30–45 mg/kg tid/bid {{or}} [[meropenem]] 6g tid
:::* Methicillin resistant
:::* Methicillin resistant
::::* Preferred regimen: [[Vancomycin]] 30–45 mg/kg tid/bid
::::* Preferred regimen: [[Vancomycin]] 30–45 mg/kg/day IV q8–12h
::::* Alternative regimen: [[Trimethoprim-sulfamethoxazole]] 10–20 mg/kg bid-qid {{or}} [[linezolid]]
::::* Alternative regimen: [[Trimethoprim-Sulfamethoxazole]] 10–20 mg/kg/day q6–12h {{or}} [[Linezolid]] 600 mg IV q12h


::* '''Staphylococcus epidermidis'''
:::* Preferred regimen: [[Vancomycin]] 30–45 mg/kg/day IV q8–12h
:::* Alternative regimen: [[Linezolid]] 600 mg IV q12h


::* '''Enterococcus species'''
:::* Ampicillin susceptible
::::* Preferred regimen: [[Ampicillin]] 12 g/day IV q4h {{and}}  [[Gentamicin]] 5 mg/kg/day IV q8h


::* Staphylococcus epidermidis
:::* Ampicillin resistant
:::* Preferred regimen: [[Vancomycin]] 30–45 mg/kg tid/bid
::::* Preferred regimen: [[Vancomycin]] 30–45 mg/kg/day IV q8–12h {{and}}  [[Gentamicin]] 5 mg/kg/day IV q8h
:::* Alternative regimen: [[Linezolid]]


::* Enterococcus species
:::* Ampicillin susceptible
::::* Preferred regimen:  [[ampicillin]] 12g 6 times per day {{and}} [[gentamicin]] 5 mg/kg tid
:::* Ampicillin resistant
::::* Preferred regimen: [[Vancomycin]] 30–45 mg/kg tid/bid {{and}} [[gentamicin]] 5 mg/kg tid
:::* Ampicillin and vancomycin resistant
:::* Ampicillin and vancomycin resistant
::::* Preferred regimen: [[Linezolid]]
::::* Preferred regimen: [[Linezolid]] 600 mg IV q12h
 
 


:* Pediatric dose:
:* Pediatric dose:
Line 213: Line 206:
:::* Neonates age 8–28 days: 30–45 mg/kg/day q6–8h
:::* Neonates age 8–28 days: 30–45 mg/kg/day q6–8h
:::* Infants and children: 60 mg/kg/day q6h
:::* Infants and children: 60 mg/kg/day q6h
==References==
{{reflist|2}}

Latest revision as of 22:41, 8 June 2015

  • Bacterial meningitis[1]
  • Empiric antimicrobial therapy based on specific predisposing factors
  • Age
  • Age < 1 month
  • Common causative pathogens: Streptococcus agalactiae, Escherichia coli, Listeria monocytogenes, Klebsiella species
  • Preferred regimen: Ampicillin 12 g/day IV q4h AND (Cefotaxime 8–12 g/day q4–6h OR Amikacin 15 mg/kg/day IV q8h OR Gentamicin 5 mg/kg/day IV q8h OR Tobramycin 5 mg/kg/day IV q8h)
  • Age 1–23 months
  • Common causative pathogens: Streptococcus pneumoniae, Neisseria meningitidis, S. agalactiae, Haemophilus influenzae, E. coli
  • Preferred regimen: Vancomycin 30–45 mg/kg/day IV q8–12h AND (Ceftriaxone 4 g IV q12–24h OR Cefotaxime 8–12 g/day q4–6h)
  • Age 2–50 years
  • Common causative pathogens: N . meningitidis, S. pneumoniae
  • Preferred regimen: Vancomycin 30–45 mg/kg/day IV q8–12h AND (Ceftriaxone 4 g IV q12–24h OR Cefotaxime 8–12 g/day q4–6h)
  • Age > 50 years
  • Common causative pathogens: S. pneumoniae, N. meningitidis, L. monocytogenes, aerobic Gram-negative bacilli
  • Preferred regimen: Vancomycin 30–45 mg/kg/day IV q8–12h AND Ampicillin 12 g/day IV q4h AND (Ceftriaxone 4 g IV q12–24h OR Cefotaxime 8–12 g/day q4–6h)
  • Head trauma
  • Basilar skull fracture
  • Common causative pathogens: S. pneumoniae, H. influenzae, group A β-hemolytic streptococci
  • Preferred regimen: Vancomycin 30–45 mg/kg/day IV q8–12h AND (Ceftriaxone 4 g IV q12–24h OR Cefotaxime 8–12 g/day q4–6h)
  • Penetrating trauma
  • Common causative pathogens: Staphylococcus aureus, coagulase-negative staphylococci (especially Staphylococcus epidermidis), aerobic Gram-negative bacilli (including Pseudomonas aeruginosa)
  • Preferred regimen: Vancomycin 30–45 mg/kg/day IV q8–12h AND Cefepime 6 g/day IV q8h OR Ceftazidime 6 g/day IV q8h OR Meropenem 6 g/day IV q8h
  • Postneurosurgery
  • Common causative pathogens: Aerobic Gram-negative bacilli (including P. aeruginosa), S. aureus, coagulase-negative staphylococci (especially S. epidermidis)
  • Preferred regimen: Vancomycin 30–45 mg/kg/day IV q8–12h AND Cefepime 6 g/day IV q8h OR Ceftazidime 6 g/day IV q8h OR Meropenem 6 g/day IV q8h
  • CSF shunt
  • Common causative pathogens: Coagulase-negative staphylococci (especially S. epidermidis), S. aureus, aerobic Gram-negative bacilli (including P. aeruginosa), Propionibacterium acnes
  • Preferred regimen: Vancomycin 30–45 mg/kg/day IV q8–12h AND Cefepime 6 g/day IV q8h OR Ceftazidime 6 g/day IV q8h OR Meropenem 6 g/day IV q8h
  • CSF Gram stain-directed antimicrobial therapy
  • Gram positive, lancet-shaped diplococci suggestive of Streptococcus pneumoniae
  • Gram negative diplococci suggestive of Neisseria meningitidis
  • Gram positive, short bacilli suggestive of Listeria monocytogenes
  • Gram positive cocci in short chains suggestive of Streptococcus agalactiae
  • Gram negative coccobacilli suggestive of Haemophilus influenzae
  • Gram negative bacilli suggestive of Escherichia coli
  • Pathogen-directed antimicrobial therapy
  • Streptococcus pneumoniae
  • Penicillin MIC < 0.1 μg/mL
  • Penicillin MIC 0.1–1.0 μg/mL
  • Penicillin MIC ≥ 2.0 μg/mL
  • Cefotaxime or ceftriaxone MIC ≥ 1.0 μg/mL
  • Neisseria meningitidis
  • Penicillin MIC < 0.1 μg/mL
  • Penicillin MIC 0.1–1.0 μg/mL
  • Listeria monocytogenes
  • Streptococcus agalactiae
  • Escherichia coli and other Enterobacteriaceae
  • Pseudomonas aeruginosa
  • Haemophilus influenzae
  • β-Lactamase negative
  • β-Lactamase positive
  • Staphylococcus aureus
  • Methicillin susceptible
  • Methicillin resistant
  • Staphylococcus epidermidis
  • Preferred regimen: Vancomycin 30–45 mg/kg/day IV q8–12h
  • Alternative regimen: Linezolid 600 mg IV q12h
  • Enterococcus species
  • Ampicillin susceptible
  • Ampicillin resistant
  • Ampicillin and vancomycin resistant
  • Pediatric dose:
  • Neonates age 0–7 days: 15–20 mg/kg/day q12h
  • Neonates age 8–28 days: 30 mg/kg/day q8h
  • Infants and children: 20–30 mg/kg/day q8h
  • Neonates age 0–7 days: 150 mg/kg/day q8h
  • Neonates age 8–28 days: 200 mg/kg/day q6–8h
  • Infants and children: 300 mg/kg/day q6h
  • Infants and children: 150 mg/kg/day q8h
  • Neonates age 0–7 days: 100–150 mg/kg/day q8–12h
  • Neonates age 8–28 days: 150–200 mg/kg/day q6–8h
  • Infants and children: 225–300 mg/kg/day q6–8h
  • Neonates age 0–7 days: 100–150 mg/kg/day q8–12h
  • Neonates age 8–28 days: 150 mg/kg q8h
  • Infants and children: 150 mg/kg
  • Infants and children: 80–100 mg/kg/day q12–24h
  • Neonates age 0–7 days: 25 mg/kg/day q24h
  • Neonates age 8–28 days: 50 mg/kg/day q12–24h
  • Infants and children: 75–100 mg/kg/day q6h
  • Neonates age 0–7 days: 5 mg/kg/day q12h
  • Neonates age 8–28 days: 7.5 mg/kg/day q8h
  • Infants and children: 7.5 mg/kg/day q8h
  • Infants and children: 120 mg/kg/day q8h
  • Neonates age 0–7 days: 75 mg/kg/day q8–12h
  • Neonates age 8–28 days: 100–150 mg/kg/day q6–8h
  • Infants and children: 200 mg/kg/day q6h
  • Neonates age 0–7 days: 75 mg/kg/day q8–12h
  • Neonates age 8–28 days: 150–200 mg/kg/day q6–8h
  • Infants and children: 200 mg/kg/day q6h
  • Neonates age 0–7 days: 0.15 MU/kg/day q8–12h
  • Neonates age 8–28 days: 0.2 MU/kg/day q6–8h
  • Infants and children: 0.3 MU/kg/day q4–6h
  • Neonates age 8–28 days: 10–20 mg/kg/day q12h
  • Infants and children: 10–20 mg/kg/day q12–24h
  • Neonates age 0–7 days: 5 mg/kg/day q12h
  • Neonates age 8–28 days: 7.5 mg/kg/day q8h
  • Infants and children: 7.5 mg/kg/day q8h
  • Infants and children: 10–20 mg/kg q6–12h
  • Neonates age 0–7 days: 20–30 mg/kg/day q8–12h
  • Neonates age 8–28 days: 30–45 mg/kg/day q6–8h
  • Infants and children: 60 mg/kg/day q6h
  1. ↑ Tunkel, Allan R.; Hartman, Barry J.; Kaplan, Sheldon L.; Kaufman, Bruce A.; Roos, Karen L.; Scheld, W. Michael; Whitley, Richard J. (2004-11-01). "Practice guidelines for the management of bacterial meningitis". Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 39 (9): 1267–1284. doi:10.1086/425368. ISSN 1537-6591. PMID 15494903.
Retrieved from "https://www.wikidoc.org/index.php?title=Sandbox_g32&oldid=1107449"